1380 RESULTS
CONFERENCE COVERAGE 2006-11-05 Conference Coverage To what extent is AD an acceleration of normal aging? This decades-old question receded in favor of the view that AD is a separate process from normal aging when studies showed that patterns of neuronal loss are different in aging and
CONFERENCE COVERAGE 2006-11-05 Conference Coverage Genomic/proteomic/metabolomics (OMICS) research in AD remains in its infancy. Most studies stall after discovering lists of hundreds of genes whose expression changes in the chosen comparison. Few groups have been able to validate thei
CONFERENCE COVERAGE 2006-11-05 Conference Coverage I. Immune mechanisms in aging and Alzheimer disease Determine whether endogenous immune mechanisms in the brain can be modulated to alter brain function or disease processes. Study differences between immune modulation in mice and huma
CONFERENCE COVERAGE 2006-11-03 Conference Coverage The yin and yang of transforming growth factor β (TGF-β) is nowhere more apparent than in Alzheimer disease. It’s been known for over a decade that expression of the cytokine is increased in AD brain (Flanders et al., 1995). Tony Wyss-
CONFERENCE COVERAGE 2006-10-31 Conference Coverage In neurons, APP-laden vesicles powered by kinesin motors ride from the cell body out to synapses. But is APP just a passenger, or does the protein sit in the driver’s seat? New work from Elaine Bearer of Brown University in Providence,
CONFERENCE COVERAGE 2006-10-28 Conference Coverage On Friday, October 13, the day before the kick-off of the Society for Neuroscience meeting in Atlanta, Lary Walker of Emory University, Atlanta, Georgia, and Richard Kostrzewa of East Tennessee State University in Johnson City, hosted
CONFERENCE COVERAGE 2006-09-15 Conference Coverage This story closes our coverage of the 10th International Conference on Alzheimer’s Disease and Related Disorders, held last July in Madrid. See PDF of this story. 15 September 2006. Bid adios to this news-rich conference by reading abo
CONFERENCE COVERAGE 2006-09-14 Conference Coverage Frequently in Alzheimer research, new trends take form when epidemiologic studies suggest an association between the risk of developing Alzheimer disease and some second factor. One such area that is growing in strength is the overlap
CONFERENCE COVERAGE 2006-09-13 Conference Coverage Norman Relkin, at Weill Medical College of Cornell University in New York, presented the latest data on his efforts to test intravenous immunoglobulin (IVIg), a somewhat mysterious mixture of purified human polyclonal antibodies origin
CONFERENCE COVERAGE 2006-09-12 Conference Coverage Nerve growth factor gene therapy, diabetes drugs, a pooled antibody stew, hormones, and radical scavengers—it’s not like all researchers are focusing squarely on immunotherapy or secretase inhibitors in their search for better Alzheime
CONFERENCE COVERAGE 2006-08-02 Conference Coverage The 10th International Conference on Alzheimer’s Disease and Related Disorders, held earlier this month in Madrid, offered its share of data on the intricate ways by which the γ-secretase enzyme complex spews out a slew of different fo
CONFERENCE COVERAGE 2006-08-01 Conference Coverage This concludes our 3-part series. Also see part 1 and part 2 or download PDF. Scientists continue to debate the relative merit of using N-terminal versus mid-section or C-terminal antibodies, and of using antibodies against soluble ver
CONFERENCE COVERAGE 2006-08-01 Conference Coverage This is part 2 of our 3-part series. Also see part 1 and part 3 or download PDF. Whatever the fallout of the AN1792 debacle, it has not stopped commercial or academic interest in immunotherapy. Elan Pharmaceuticals and its partner Wyet
CONFERENCE COVERAGE 2006-07-31 Conference Coverage This is part 1 of our 3-part series. Also see part 2 and part 3 or download PDF. Immunotherapy may not be the most eclectic choice of subject for those news aficionados who thirst for something completely different. Yet as the bearer o
CONFERENCE COVERAGE 2006-07-28 Conference Coverage This is part 2 of our 3-part series. Also see part 1 and part 3 or download PDF. Anti-BACE Drugs Appear on Horizon On BACE inhibition, Martin Citron of Amgen in Thousands Oaks, California, noted that more than 100 patent applications h
